GLGuona Li

Guona Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guona Li has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Huangan Wu

    Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    4 shared publications
  • Zhaoqin Wang

    Department of Aeronautics and Astronautics, Shanghai Key Laboratory of Acupuncture Mechanism and Acupoint Function, Fudan University, Shanghai, China

    4 shared publications
  • Lu Zhu

    3 shared publications
  • Hui-Rong Liu

    Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China

    2 shared publications
  • Huirong Liu

    Shanghai Research Institute of Acupuncture and Meridian, Shanghai 200030, China

    2 shared publications
  • Jing Li

    Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications

Latest Publications

  • Effects of mild moxibustion at Zusanli (ST36) on hematopoietic function and expression of Notch signaling pathway-related factors in aplastic anemia mice

    by Jianfei Shi, Li Qi, Lianrui Qin, Danli Jiao, Yutong Qian, Shimin Liu, Chang Liu, Jing Li, Lingxiang Wu, Guona Li, et al.

  • Open Access

    Nomogram for predicting cancer-specific mortality risk in endometrial cancer after postoperative radiotherapy

    by Qingyi Wang, Ailin Tao, Yinfeng Tuo, Jiali Li, Fanglei Liu, Zhihui Deng, Guona Li

    Background: Endometrial cancer (EC) incidence keeps rising amid population aging and obesity. This study aimed to investigate independent prognostic factors for the overall survival (OS) and cancer-specific survival (CSS) in postmenopausal EC patients treated with surgery and radiotherapy, and to construct a nomogram to predict survival rate. Methods: We analyzed postmenopausal EC patients who had undergone surgery and radiotherapy between 2010 and 2015, using data from the Surveillance Epidemiology and End Results (SEER) database. The patients were divided into the training and validation cohorts using a ratio of 7:3. Prognostic factors were identified using univariate and multivariate analyses, and a nomogram was developed to predict OS and CSS using Cox proportional hazards and Fine-Gray compete-risk models. We evaluated the nomogram’s performance using C-index, receiver operating characteristic (ROC) curve, and calibration plot, and compared it with American Joint Committee on Cancer (AJCC) staging model to assess the impact of surgical modality, radiotherapy modality, chemotherapy or not, and pathological types on OS in different risk stratifications. Results: A total of 10,906 EC patients were enrolled in the study and randomly assigned to the training (n=7,633) and validation (n=3,273) cohorts. The competing risk nomogram finalized 13 prognostic variables including age, tissue type, brain metastasis, lung metastasis, marital status, T-stage, N-stage, stage, grade, radiotherapy modality, tumor size, surgical site, and regional lymphadenectomy. The nomogram showed good performance in predicting CSS with C-indexes of 0.800 and 0.755 for the training and validation sets, respectively. The nomogram performed significantly better than AJCC staging model. In addition to the above variables, the Cox proportional hazards model incorporated bone metastasis, chemotherapy, and the total number of in situ/malignant tumors, with the C-index of the training set being 0.753 and 1-, 3-, and 5-year areas under the curve (AUCs) being 0.825, 0.785, and 0.772, respectively. The calibration plots showed good consistency. Subgroup analysis showed that the low-risk and high-risk groups showed that patients receiving radiotherapy had longer survival times compared to those receiving chemoradiotherapy, and patients undergoing brachytherapy had longer survival times compared to those receiving external beam radiotherapy (EBRT). Conclusions: Our study developed and validated a nomogram for predicting OS and CSS in postmenopausal EC patients treated with surgery and radiotherapy. These findings provide valuable insights for individualized risk assessment and treatment decision.

  • Open Access

    Exploring the Relationship Between Colitis-Associated Cancer and Lipid Metabolism Reprogramming from the Perspective of Inflammation-Cancer Transformation

    by ShuangShuang Zhang, Kunshan Li, Dong-Dong Yu, Ya-Ying Lin, Lu Zhu, Pei-Han Wang, Guo-Na Li, Yan Huang, Hong-Xiao Xu, Ming Zhang

    Colitis-associated colorectal cancer (CAC) is the most severe complication of inflammatory bowel disease (IBD), characterized by multifocal lesions and poor prognosis. Aberrant lipid metabolism drives CAC progression by modulating the tumor microenvironment, activating oncogenic pathways, and facilitating immune escape. These metabolic alterations supply energy for tumor cells, disrupt the homeostasis of the tumor microenvironment, and contribute to gut microbiota dysbiosis, ultimately establishing a vicious cycle of “metabolism–inflammation–carcinogenesis.” Although the role of lipid metabolism in sporadic colorectal cancer has been extensively studied, the specific metabolic rewiring that triggers the malignant switch during chronic colitis remains systematically unexplored. From the viewpoint of the dynamic transition toward malignancy, this review dissects the synergistic interactions between lipid metabolism and inflammatory signaling, immune microenvironment remodeling, and intestinal dysbiosis during this evolutionary process. It systematically summarizes key genes and potential therapeutic targets governing lipid metabolism in CAC and investigates the translational value of targeting lipid metabolic reprogramming for early intervention and combination therapies in CAC. By integrating current evidence, this article clarifies how lipid reprogramming orchestrates the inflammation-to-cancer shift, providing novel research insights and therapeutic strategies to improve clinical prognosis for CAC patients.

  • Open Access

    Electroacupuncture and Moxibustion Regulate Aerobic Glycolysis and Alleviate Tumor Progression in Mice with Hepatocellular Carcinoma

    by Rui Zhong, Huangan Wu, Lu Zhu, Xiaowen Zhang, Yanxia Chen, Qin Qi, Guona Li, Zhaoqin Wang, Yan Huang, Zhihui Deng, et al.

    Aerobic glycolysis is crucial in the proliferation, metastasis, immunosuppression of hepatocellular carcinoma (HCC). We established mice model with HCC to explore whether electroacupuncture and moxibustion can alleviate HCC mice by inhibiting NSUN2-mediated aerobic glycolysis. HCC mice model was established by intraperitoneal injection of diethylnitrosamine combined with carbon tetrachloride. In the moxibustion and electroacupuncture groups, the acupoints “Ganshu” and “Zusanli” (bilateral) were selected for intervention. Enzyme-linked immunosorbent assay quantified the serum levels. Immunohistochemistry/Western blotting, quantitative real-time PCR assessed protein and mRNA expressions of aerobic glycolysis. MRM-based targeted metabolomics quantified hepatic energy metabolism alterations. After HCC model completion on week 28, macroscopic examination revealed pronounced hepatomegaly with evident morphological distortion. The hepatic surface exhibited a coarse and irregular texture, accompanied by varying degrees of adhesions between adjacent liver lobes. Notably, large, well-defined tumors presenting in either whitish or dark-red appearances were observed scattered across the liver parenchyma. Following a total intervention period of 26 weeks, electroacupuncture and moxibustion significantly decreased the number of liver tumor, tumor load, mean tumor diameter and tumor volume compared to the model group (P < 0.05). Furthermore, the spleen and liver index were also significantly lowered (P < 0.05). A significant decrease was observed in the protein levels of serum AFP and AFP-L3 after treatment (P < 0.05). The protein and mRNA expression levels of NSUN2 and PKM2 were significantly downregulated (P < 0.01). Consistent with the inhibition of glycolytic flux, the protein expression of enzyme hexokinase 2 (HK2) was profoundly reduced (P < 0.001). Meanwhile, moxibustion decreased in the hepatic content of early glycolytic intermediates, glucose-6-phosphate (G6P) and fructose 6 phosphate (F6P) (P < 0.01), and electroacupuncture just decreased G6P (P < 0.001). Conversely, the level of phosphoenolpyruvate, a high-energy intermediate preceding the final step of glycolysis, was significantly elevated and increased (P < 0.001). The study reveals that both electroacupuncture and moxibustion alleviate tumor proliferation in HCC mice by suppressing the NSUN2-PKM2 glycolytic axis, thereby highlighting this pathway as a novel metabolic target for non-pharmacological intervention; moreover, moxibustion uniquely exhibits the potential to induce a more extensive metabolic stress response. The observed reductions in tumor burden and key biomarkers corroborate the therapeutic potential of this approach. Collectively, these preclinical findings suggest that electroacupuncture and moxibustion, as non-pharmacological adjunctive therapies, hold translational potential for modulating tumor metabolism and slowing HCC progression, warranting further clinical investigation.

  • Open Access

    Electroacupuncture alleviates Parkinson’s disease by targeting HDAC/SIRT-mediated deacetylation of 14-3-3

    by Zhao-Qin Wang, Han-Dan Zheng, Ling-Jie Li, Lu-Lu Cao, Lin Shen, Yu Qiao, Yi-Yi Chen, Lu-Yi Wu, Guo-Na Li, Huan-Gan Wu

    Introduction: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons and the accumulation of pathological α -synuclein. Although current treatments can alleviate symptoms, they do not modify disease progression. Growing evidence implicates gut microbiota dysbiosis and aberrant protein acetylation in PD pathogenesis. Electroacupuncture (EA) has shown therapeutic potential in PD; however, its effects on protein acetylation remain unclear. Methods: A PD mouse model was established through MPTP induction and fecal microbiota transplantation (FMT) from PD patients. Mice received EA stimulation at Baihui (GV20) and Yanglingquan (GB34) acupoints for 14 days. Behavioral tests, immunohistochemistry, Western blot, qPCR, and 4D label-free acetyl proteomics were employed to assess motor function, neuronal integrity, protein expression, and acetylation profiles. Results: EA significantly improved motor coordination, enhanced sensorimotor function in the adhesive removal test, and increased open-field activity in PD mice. It attenuated the loss of tyrosine hydroxylase–positive neurons and decreased α -synuclein accumulation in the substantia nigra. Proteomic analysis revealed hyperacetylation of Ywhaq (14-3-3) in PD mice, which was reversed by EA. Mechanistically, EA upregulated the expression of deacetylases HDAC1/2/3 and SIRT1/2 at both protein and mRNA levels, restoring acetylation homeostasis. Conclusion: Electroacupuncture ameliorates behavioral and neuropathological phenotypes in a PD mouse model by restoring deacetylase expression and normalizing protein acetylation, particularly of 14-3-3. Our results underscore the therapeutic potential of EA and highlight acetylation modulation as a promising strategy for PD treatment.


  • Open Access

    Treatment of Moderate-to-Severe Pain in Hepatocellular Carcinoma with Transcutaneous Electrical Acupoint Stimulation: A Randomized Controlled Trial

    by Lu Zhu, Jing Li, Zhao-Qin Wang, Yun-Jia Gu, Guo-Na Li, Wen-Jia Wang, Guang-Bin Pen, Qi Li, Meng-Die Wu, Hui-Rong Liu, et al.

    Objective: Moderate-to-severe pain is the most common clinical symptom in patients with hepatocellular carcinoma (HCC).This trial aimed to analyze the clinical efficacy of Transcutaneous electrical acupoint stimulation (TEAS) in patients of HCC with severe pain and provide a reliable reference for optimizing the clinical diagnostic and therapeutic strategies of HCC. Methods: A total of 104 eligible patients were randomly allocated to experimental and control groups in a ratio of 1:1.The treatment was administered for 1 week continuously. Patients in both groups were followed up 1 week after the end of the treatment.The primary outcome measure was the Numerical Rating Scale (NRS) score, whereas the secondary outcome measures included Brief Pain Inventory BPI-Q3, Q4, Q5 scores, analgesic dose, frequency of opioid-induced gastrointestinal side effects, Karnofsky Performance Status (KPS), Quality of Life Scale - Liver Cancer (QOL-LC), and Brief Fatigue Inventory (BFI) scores. Results: The NRS scores of experimental group was significantly lower after treatment and at the follow-up than baseline (average P< 0.01), there were also statistical differences between the groups at the above time points (average P< 0.01). BPI-Q3, -Q4, and -Q5 scores in the experimental group were decreased after treatment when compared with those before treatment (average P< 0.01). Furthermore, there were significant improvements of gastrointestinal side effects, KPS, QOL-LC and BPI in the experimental group after treatment, and the above results were statistically significant compared to the control group. Conclusion: 7-day TEAS treatment can significantly enhance the analgesic effect and maintain for the following week, also reduce the incidence of gastrointestinal side effects caused by opioids, and improve the quality of life of patients with moderate-to-severe HCC-related pain, which has reliable safety and certain clinical promotion value.


  • Open Access

    Mild moxibustion for Irritable Bowel Syndrome with Diarrhea (IBS-D): A randomized controlled trial

    by Zhaoqin Wang, Manwen Xu, Zheng Shi, Chunhui Bao, Huirong Liu, Cili Zhou, Yilu Yan, Chunye Wang, Guona Li, Wei Zhang, et al.


  • Open Access

    Electroacupuncture Improves IBS Visceral Hypersensitivity by Inhibiting the Activation of Astrocytes in the Medial Thalamus and Anterior Cingulate Cortex

    by Min Zhao, Zhaoqin Wang, Zhijun Weng, Fang Zhang, Guona Li, Zhe Ma, Huangan Wu, Yuhu Xin, Huirong Liu, Jimeng Zhao

    Objective. To explore whether the effect of electroacupuncture (EA) on visceral hypersensitivity (VH) in rats with irritable bowel syndrome (IBS) is related to the changes of astrocyte activation in the medial thalamus (MT) and anterior cingulate cortex (ACC). Method. Male Sprague‐Dawley rats were randomly divided into the normal control (NC) group, model control (MC) group, electroacupuncture (EA) group, and fluorocitrate (FCA) group. A model of visceral hypersensitivity was established by neonatal colorectal irritation. In the EA group, needles were inserted into the skin at the Tianshu (ST25) and Shangjuxu (ST37) acupoints, once a day for 7 days. The FCA group received intrathecal injection of FCA on the 1st, 4th, and 7th days. Visceral hypersensitivity was evaluated by the abdominal withdrawal reflex (AWR), and glial fibrillary acidic protein (GFAP) mRNA and protein levels in the MT and ACC were detected by real‐time PCR, immunohistochemistry, and western blots. Results. The AWR score in the MC group was significantly higher than in the NC group, and EA and FCA reduced the AWR score of VH rats. GFAP mRNA and protein levels in the MT and ACC of rats in the MC group were significantly increased compared with the NC group. After either electroacupuncture or fluorocitrate, GFAP mRNA and protein levels in the MT and ACC were both clearly reduced. Conclusion. Electroacupuncture alleviates IBS visceral hypersensitivity by inhibiting the activation of astrocytes in the MT and ACC.


  • Open Access

    Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome

    by Chun-Hui Bao, Chun-Ye Wang, Guo-Na Li, Yi-Lu Yan, Di Wang, Xiao-Ming Jin, Lu-Yi Wu, Hui-Rong Liu, Xiao-Mei Wang, Zheng Shi, et al.

    Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome